Alnylam Pharmaceuticals | ALNY - Net Income

Stock Price
457.50
Daily Change
5.50 1.22%
Monthly
5.17%
Yearly
80.72%
Q3 Forecast
448.25

Alnylam Pharmaceuticals reported $-66277000 in Net Income for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 4.57B
Cash and Equivalent USD 1.11B
Cost of Sales USD 142.95M
Current Assets USD 3.64B
Current Liabilities USD 1.3B
Debt USD 1.3B
EBIT USD 4.89M
EBITDA USD 18.83M
Employees 2.23K
EPS Earnings Per Share USD 0.32
Equity Capital and Reserves USD 250.59M
Gross Profit on Sales USD 630.74M
Interest Expense on Debt USD 40.25M
Interest Income USD 27.49M
Loan Capital USD 1.03B
Market Capitalization USD 59.08B
Net Income USD -66.28M
Operating Expenses USD 789.89M
Operating Profit USD -16.2M
Ordinary Share Capital USD 130.98M
Pre-Tax Profit USD -35.36M
Sales Revenues USD 773.69M
Selling and Administration Expenses USD 323.31M
Stock USD 71.69M
Trade Creditors USD 102.39M
Trade Debtors USD 567.11M

Net Income Change Date
Acadia Pharmaceuticals USD 26.67M 7.68M Jun/2025
Agios Pharmaceuticals USD -112020000 22.73M Jun/2025
Alnylam Pharmaceuticals USD -66277000 8.8M Jun/2025
Amgen USD 1.43B 298M Jun/2025
Arrowhead Research USD -175241000 545.69M Jun/2025
BioMarin Pharmaceutical USD 240.53M 54.85M Jun/2025
Incyte USD 405M 246.8M Jun/2025
Ionis Pharmaceuticals USD 123.55M 270.49M Jun/2025
Moderna USD -825000000 146M Jun/2025
Neurocrine Biosciences USD 107.5M 99.6M Jun/2025
Novartis USD 4.04B 1.22B Jun/2025
PTC Therapeutics USD -64849000 931.41M Jun/2025
Regeneron Pharmaceuticals USD 1.39B 582.9M Jun/2025
Sanofi EUR 3.94B 3.44B Jun/2025
Sarepta Therapeutics USD 196.89M 644.4M Jun/2025
Takeda JPY 124.24B 227.4B Jun/2025
Tectonic Therapeutic USD -19980000 7.61M Jun/2025
Ultragenyx Pharmaceutical USD -114951000 36.13M Jun/2025
Vertex Pharmaceuticals USD 1.03B 386.6M Jun/2025
Xencor USD -30825000 17.59M Jun/2025